Symbols / APM

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Price estimates from analyst targets and simple models.

• (APM) Advanced Trading Insights (APM:CA) - Stock Traders Daily ue, 17 Feb 2026 19
• Insiders own 26% of APM Automotive Holdings Berhad (KLSE:APM) shares but private companies control 47% of the company - Yahoo Finance Mon, 06 Oct 2025 07
• Aptorum Group Sets March 10, 2026 Date for 2025 Annual General Meeting - The Globe and Mail Fri, 06 Feb 2026 21
• Aptorum To Merge With DiamiR In All-stock Deal, Stock Up In Pre-market - Nasdaq Wed, 16 Jul 2025 07
• Why Is Aptorum Stock (APM) Up 115% Today? - TipRanks hu, 21 Aug 2025 07
• Aptorum Group Regains Compliance with Nasdaq's Minimum Bid Price Requirement - Quiver Quantitative Mon, 04 Aug 2025 07
• APM Industries Downgraded to Strong Sell Amid Technical and Fundamental Weakness - Markets Mojo Mon, 16 Feb 2026 16
• Is Andean Precious Metals Corp.'s (TSE:APM) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st Mon, 05 Jan 2026 08
• APM Stock Skyrockets: Next Steps? - StocksToTrade Wed, 16 Jul 2025 07
• Are Robust Financials Driving The Recent Rally In Andean Precious Metals Corp.'s (TSE:APM) Stock? - Yahoo Finance Fri, 09 Jan 2026 08
• Aptorum Updates Investors With Interim and Pro Forma Financials Ahead of DiamiR Merger - The Globe and Mail Fri, 23 Jan 2026 08
• Subdued Growth No Barrier To Andean Precious Metals Corp. (TSE:APM) With Shares Advancing 25% - simplywall.st hu, 09 Oct 2025 07
• We Think That There Are More Issues For Andean Precious Metals (TSE:APM) Than Just Sluggish Earnings - Yahoo Finance Wed, 20 Aug 2025 07
• Andean Precious Metals CEO Launches C$83.1 Million Secondary Share Offering to Boost Liquidity - TipRanks Fri, 23 Jan 2026 08
• Andean Precious Metals (TSX:APM) Is Up 17.1% After Earnings Surge and Insider Selling – Has Sentiment Shifted? - Yahoo Finance Wed, 12 Nov 2025 08

• Income Statement
• Balance Sheet
• Cash Flow

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).